A prospective study of variability in glycemic control during different phases of the menstrual cycle in type 2 diabetic women using high sensitivity C - Reactive protein

Journal of Clinical and Diagnostic Research

Volumn 8, Issue 4, 2014, Pages

  Gugapriya, T S ^a   Karthick, S ^b   Nagarjuna, B ^b  

^a Chennai Medical College Hospital and Research Centre   (India)

^b Adhiparasakthi Engineering College   (India)

Author keywords

Biomarker; Fasting blood glucose level; Glycemic control; Hs crp; Luteal phase; Menstrual cycle; Type2 diabetic female

Indexed keywords

C REACTIVE PROTEIN; ESTRADIOL; PROGESTERONE;

ADULT; ARTICLE; CLINICAL ARTICLE; DRIED BLOOD SPOT TESTING; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; FOLLICULAR PHASE; GLUCOSE BLOOD LEVEL; GLYCEMIC CONTROL; HUMAN; LUTEAL PHASE; MENSTRUAL CYCLE; NON INSULIN DEPENDENT DIABETES MELLITUS; OVULATION DETECTION; PROSPECTIVE STUDY;

EID: 84898648540     PISSN: 2249782X     EISSN: 0973709X     Source Type: Journal    
DOI: 10.7860/JCDR/2014/8118.4240     Document Type: Article

References (41)

1. Chen KW, et al. Earlier appearance of impaired insulin secretion than of visceral adiposity in the pathogenesis of NIDDM. 5-Year follow-up of initially non diabetic Japanese-American men. Diabetes Care. 1995; 18:747.
2. Gerald M Reaven. Role of Insulin Resistance in Human Disease. Diabetes.1988; 37(12): 1595-607.
3. Stumvoll M, et al. Type 2 diabetes: principles of pathogenesis and therapy. Lancet. 2005; 365:1333.
4. Devaraj S, et al. Hyperglycemia induces monocytic release of interleukin-6 via induction of protein kinase c-{alpha} and - {beta}. Diabetes. 2005; 54:85-91.
5. Welled KE, Hotamisligil GS. Inflammation, stress, and diabetes. Clin. Invest. 2005; 115(5):1111-19.
6. Abbatecola AM, et al. Diverse effect of inflammatory markers on insulin resistance and Insulin-resistance syndrome in the elderly. J Am Geriatric Soc. 2004; 52(3):399-404.
7. Barbara Thorand, et al. Sex differences in the prediction of type 2 diabetes by inflammatory markers. Diabetes care. 2007; 30(4):854-60.
8. Duncan BB, et al. Low-grade systemic inflammation and the development of type 2 diabetes: the atherosclerosis risk in communities study. Diabetes.2003 Jul; 52(7):1799-805.
9. Aronson D, et al. Association between fasting glucose and C-reactive protein in middle-aged subjects. Diabet. Med. 2004 Jan; 21(1):39-44.
10. Durga Prasanna Misra, et al. Prevalence of Inflammatory Markers (High-Sensitivity C-reactive protein, Nuclear Factor-kb, and Adiponectin) in Indian Patients with Type 2 Diabetes Mellitus with and without Macrovascular Complications. Metabolic syndrome and related disorders. 2012; 10(3): 209-13.
11. Paulm Ridker, et al. C-reactive protein and other markers of inflammation in the prediction of cardiovascular disease in women. N Engl J Med. 2000; 342:836-43.
12. Ford ES. The metabolic syndrome and C-reactive protein, fibrinogen and leukocyte count: findings from the third national health and nutrition examination survey. Atherosclerosis. 2003; 168:351-8.
13. Pradhan AD, et al. C-reactive protein, interleukin6 and risk of developing type 2 diabetes mellitus. JAMA. 2001; 286: 327-34.
14. Claudine A Blum, et al. Low-Grade Inflammation and Estimates of Insulin Resistance during the Menstrual Cycle in Lean and Overweight Women.The Journal of Clinical Endocrinology & Metabolism. 2005; 90(6):3230-5.
15. Nakanishi N, Shiraishi T, Wada M. C-reactive protein concentration is more strongly related to metabolic syndrome in women than in men: the MINOH Study. Circ J. 2005; 69(4):386-91.
16. Nakanishi N, Shiraishi T, Wada M. Association between fasting glucose and C-reactive protein in a Japanese population: the MINOH study. Diabetes Res Clin Pract. 2005; 69(1):88-98. Epub 2005 Jan 7.
17. Anubha Mahajan, et al. High-Sensitivity C-reactive protein Levels and Type 2 Diabetes in Urban North Indians. J Clin Endocrinol Metab. June 2009; 94(6): 2123-7.
18. Ming-May Lai, et al. Sex difference in the association of metabolic syndrome with high sensitivity C-reactive protein in a Taiwanese population. BMC public health. 2010; 10:429-36.
19. Ryuichi Kawamoto, et al. Association between fasting plasma glucose and high-sensitivity C-reactive protein: gender differences in a Japanese community-dwelling population. Cardiovascular Diabetology. 2011; 10:51-9.
20. Erkan Çoban, Ramazan Sari. The Levels of Serum High Sensitivity C - reactive protein in Subjects with Impaired Fasting Glucose. Turkish Journal of Endocrinology and Metabolism. 2003; 4: 165-8.
21. Fazlul Haque, et al. Evaluation of serum high sensitivity C - reactive protein (hs-crp) in type-2 diabetic Patient. J medicine. 2010; 11: 20-3.
22. Tajiri Y, et al. High-sensitivity C-reactive protein in Japanese patients with type 2 diabetes. Obes Res. 2005 Oct; 13(10):1810-6.
23. Sabanayagam C, et al. Serum C-reactive protein level and prediabetes in two Asian populations. Diabetologia. 2011 Apr; 54(4):767-75. Epub 2011 Jan.
24. Hannele Yki-Järvinenf. Insulin Sensitivity during the Menstrual Cycle. The Journal of Clinical Endocrinology & Metabolism. 1984; 59(2):350-3.
25. Toth EL, Suthijumroon A, Crockford PM, Ryan EA. Insulin action does not change during the menstrual cycle in normal women. J Clin Endocrinol Metab. 1987; 64(1):74-80.
26. Bingley CA, Gitau R, Lovegrove JA. Impact of Menstrual Cycle Phase on Insulin Sensitivity Measures and Fasting Lipids. Horm Metab Res. 2008; 40(12): 901-6.
27. Katherine Wander, et al. C - reactive protein Across the Menstrual Cycle, American journal of physical anthropology. 2008; 136:138-46.
28. Diamond MP, et al. Menstrual cyclicity has a profound effect on glucose homeostasis. FertilSteril. 1989 Aug; 52(2):204-8.
29. Valdes CT, Elkind-Hirsch KE. Intravenous glucose tolerance test-derived insulin sensitivity changes during the menstrual cycle. J Clin Endocrinol Metab. 1991 Mar; 72(3):642-6.
30. Jilma B, et al. Menstrual cycle-associated changes in blood levels of interleukin-6, alpha1 acid glycoprotein, and C-reactive protein. Lab Clin Med. 1997 Jul; 130(1):69-75.
31. Pacifici R, et al. Effect of surgical menopause and estrogen replacement on cytokine release from human blood mononuclear cells. Proc Natl Acad Sci USA. 1991; 88:5134-8.
32. Davison S, Davis SR. New markers for cardiovascular disease risk in women: impact of endogenous estrogen status and exogenous postmenopausal hormone therapy. J Clin Endocrinol Metab. 2003; 88:2470-8.
33. Bismar H, et al. Increased cytokine secretion by human bone marrow cells after menopause or discontinuation of estrogen replacement. J Clin Endocrinol Metab.1995; 80:3351-5.
34. Yeung EH, et al Longitudinal study of insulin resistance and sex hormones over the menstrual cycle: the BioCycle Study. J Clin Endocrinol Metab. 2010 Dec; 95(12):5435-42. Epub 2010 Sep 15.
35. Mohan V, et al. Glucose intolerance (diabetes and IGT) in selected south Indian population with special reference to family history, obesity and life style factors. The Chennai Urban Population study (CUPS 14). J. Assoc. Physicians India.2003; 51: 771-7.
36. Mohan V, et al Introduction Urban difference in the prevalence of metabolic syndrome in South India. The Chennai Urban Population study (CUPS 14). Diabet. Med. 2001; 18: 280-7.
37. Wild S, et al. Global prevalence of diabetes estimates for the year 2000 and projections for 2030. Diabetes Care. 2004;(27): 2568-9.
38. Forouhi1 NG, Sattar N and McKeigue PM. Relation of C-reactive protein to body fat distribution and features of the metabolic syndrome in Europeans and South Asians. Journal of Obesity. 2001; 25:1327-31.
39. Andreas Pfützner, et al. High-Sensitivity C-Reactive Protein Predicts Cardiovascular Risk in Diabetic and Non diabetic Patients: Effects of Insulin-Sensitizing Treatment with Pioglitazone. J Diabetes Sci Technol. 2010; 4(3):706-16.
40. O'Connor KA, et al. Ovulation detection methods for urinary hormones: precision, daily and intermittent sampling and a combined hierarchical method. Hum Reprod. 2006; 21:1442-52.
41. Thomas W. Mcdade, et al. What a drop can do: dried blood spots as a minimally invasive method for integrating Biomarkers into population-based research. Demography. 2007; 44(4): 899-925.